VY
VYNE.O
—
NASDAQ
Pharmaceuticals & Medical Research
Vyne Therapeutics Inc
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
16,6M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
-5 219,1 %
ROE
-95,4 %
Net margin
-4 646,1 %
Debt / equity
0,00
Beta
—
52w range
—
Volume
772
Day range
$0,67–$0,69
Prev close
$0,69
Open
$0,68
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Vyne Therapeutics Inc is a biotechnology company focused on the development of novel therapeutics for the treatment of rare diseases, primarily through its proprietary platform for the discovery and development of small molecule drugs.
Business. Vyne Therapeutics Inc (VYNE.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY4 analysts
2 buy2 hold0 sell
Avg 12m price target2,00
Analyst recommendations
4 analysts · consensus BuyBuy2
Hold2
Sell0
12-month price target
2,00
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
4 analysts · indicative
Ownership→
UBS Financial Services, Inc.
largest disclosed fund holder
Profitability→
-95,4 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to VYNE.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Vyne Therapeutics Inc (VYNE.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
AI synthesis
GENERATEDVyne Therapeutics operates with a strong liquidity position, as evidenced by its cash and equivalents of $24.03 million, which significantly exceeds its total liabilities of $2.395 million, resulting in a current ratio of 12.53. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating a conservative capital structure with no leverage. The company's market cap of $21.37 million is significantly lower than its book value, as reflected in a price-to-book ratio of 0.77.
The company is currently unprofitable, with a net loss of $26.48 million and an operating loss of $29.75 million in the latest reporting period. Its return on equity (ROE) is -9.54%, and its return on assets (ROA) is -8.78%, both of which are significantly below the industry median for biotechnology firms. The company's operating cash flow is negative at -$33.12 million, and its free cash flow is -$26.71 million, indicating that it is not generating positive cash from operations.
Vyne Therapeutics does not disclose segment or geographic revenue breakdowns in its latest financials, and no material revenue concentration is reported. The company's operations are primarily focused on research and development, with no disclosed revenue-generating products or services in the current period.
The company's growth trajectory is not yet defined in terms of revenue, as it has not yet achieved positive revenue growth. The company's current revenue is $570,000, and no forward-looking revenue guidance is provided in the latest filings. Analysts have assigned a mean price target of $2.00, with a median of $2.00 and a high of $2.00, suggesting a potential upside of 212% from the current market price of $0.64.
Vyne Therapeutics is currently assessed as having low liquidity and dilution risk, with no immediate filing-based flags detected. The company has not issued any new shares in the latest period, and its basic and diluted share counts are identical at 33.32 million shares. No dilution adjustments are applied in the valuation snapshot, and the company's capital structure remains unchanged.
No recent filings or transcripts are available in the provided data to indicate material events or strategic shifts in the company's operations. The company's financials suggest a continued focus on R&D with no immediate commercialization of products.
Key takeaways
- Vyne Therapeutics has a strong liquidity position with no long-term debt and a current ratio of 12.53.
- The company is currently unprofitable with a net loss of $26.48 million and negative returns on equity and assets.
- No revenue concentration or geographic exposure is disclosed, and the company has not yet commercialized any products.
- Analysts have assigned a mean price target of $2.00, suggesting a potential upside of 212% from the current market price.
- The company is assessed as having low liquidity and dilution risk, with no immediate filing-based flags detected.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$0,50
Market cap
$21.4M
Enterprise valueⓘ
-$2.7M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
0.8x
P / Tangible bookⓘ
0.8x
Tangible book
$27.8M
Net cashⓘ
$24.0M
Current ratioⓘ
12.5
Debt / equityⓘ
0.0
ROAⓘ
-87.8%
ROEⓘ
-95.4%
Cash conversionⓘ
125.0%
CapEx / revenueⓘ
0.0%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
Peer comparison8 peers · vs VYNE · multiples and returns
KL
KLAR—
KLAR.ST
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
BN
BNTX—
Biontech SE
$92,25
23,3B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
EX
EXEL—
Exelixis Inc
$55,06
14,7B USDP/E
19,5x
— vs self
Div yield
—
— vs self
ROE
40,4 %
+135,8 vs self
MD
MDGL—
Madrigal Pharmaceuticals Inc
$482,00
11,0B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-47,8 %
+47,5 vs self
IN
INSM—
Insmed Inc
$107,46
23,0B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-160,2 %
-64,8 vs self
VC
VCYT—
Veracyte Inc
$45,30
3,6B USDP/E
55,5x
— vs self
Div yield
—
— vs self
ROE
5,1 %
+100,4 vs self
MD
MDXG—
Mimedx Group Inc
$4,27
636,0M USDP/E
11,1x
— vs self
Div yield
—
— vs self
ROE
18,9 %
+114,3 vs self
AV
AVIR—
Atea Pharmaceuticals Inc
$4,61
—P/E
—
— vs self
Div yield
—
— vs self
ROE
-57,5 %
+37,9 vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-0,92
Predicted surprise
+0,00
Beat probability
45 %
Analysts
4
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-04 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,92 |
| Revenue | —no estimate | —no estimate | 700,000 USD |
| Operating income | —no estimate | —no estimate | -33,4M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution4 analysts
Strong buy0
Buy2
Hold2
Sell0
Strong sell0
12-month price target$2,00 · Median $2,00
Low $2,00High $2,00
Operating income · consensus-33,4M USD
EPS surprise
+32,2 %
reported vs consensus · beat
Revenue surprise
−18,6 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$2,00
Mean$2,00
Median$2,00
High$2,00
Spot$0,50
+300.3 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin-5 219,1 %Bottom quartile
Net Margin-4 646,1 %Bottom quartile
ROE-95,4 %Bottom quartile
Capex / Rev0,0 %Above P75
D/E0,00Above median
Cash Conv1,25Above P75
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 80 000 sh4 grants4 insiders
- Director · Stock Option (right to buy) → Common StockAcquired 20 000 @ $0,38grant · 2025-12-12
- Director · Stock Option (right to buy) → Common StockAcquired 20 000 @ $0,38grant · 2025-12-12
- Director · Stock Option (right to buy) → Common StockAcquired 20 000 @ $0,38grant · 2025-12-12
- Director · Stock Option (right to buy) → Common StockAcquired 20 000 @ $0,38grant · 2025-12-12
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
Source documents
- Vyne Therapeutics Inc Market data — financials · 2026-05-29
- Vyne Therapeutics Inc Market data — analyst estimates · 2026-05-29
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- David DomzalskiPresident, Chief Executive Officer, Director
Insider activity
Mixed / flat0 buys · 0 sellsnet $04 insiders · last 365d
- Director, PRESIDENT AND CEO · Common StockOther 30 791 @ $0,31$10K · 2026-05-29
- CHIEF SCIENTIFIC OFFICER · Common StockOther 2 876 @ $0,60$2K · 2026-03-31
- Director, PRESIDENT AND CEO · Common StockOther 14 232 @ $0,60$9K · 2026-03-31
- CHIEF LEGAL OFFICER AND GC · Common StockOther 4 007 @ $0,60$2K · 2026-03-31
- CHIEF FINANCIAL OFFICER · Common StockOther 4 007 @ $0,60$2K · 2026-03-31
- CHIEF LEGAL OFFICER AND GC · Common StockOther 3 579 @ $0,58$2K · 2025-12-31
- CHIEF FINANCIAL OFFICER · Common StockOther 7 858 @ $0,58$5K · 2025-12-31
- Director, PRESIDENT AND CEO · Common StockOther 12 684 @ $0,58$7K · 2025-12-31
- CHIEF SCIENTIFIC OFFICER · Common StockOther 2 448 @ $0,58$1K · 2025-12-31
- Director, PRESIDENT AND CEO · Common StockOther 12 676 @ $0,34$4K · 2025-09-30
- CHIEF FINANCIAL OFFICER · Common StockOther 3 420 @ $0,34$1K · 2025-09-30
- CHIEF SCIENTIFIC OFFICER · Common StockOther 2 453 @ $0,34$822 · 2025-09-30
- CHIEF LEGAL OFFICER AND GC · Common StockOther 3 581 @ $0,34$1K · 2025-09-30
Short positioning
184.0Kshares short+76.3% vs prior
1days to cover
42.6%short of daily vol
283fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
VYNE.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Evidence & claims
From filings & derived data- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -83.8%Derived (calculated)
- Net margin (FY 2025-12-31): -4,646.1%Derived (calculated)
- Return on equity (FY 2025-12-31): -95.4%Derived (calculated)
- Return on assets (FY 2025-12-31): -87.8%Derived (calculated)
- Current ratio (FY 2025-12-31): 12.53xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.09xDerived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 20.6%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 33.3%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 33.3%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 33.5%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 2.5%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 31.8%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -37.8%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 13.8%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -46.7%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -54.9%Derived (calculated)
- R&D expense (annual): USD 19.24MSEC XBRL filing
- Net income (annual): USD -26.48MSEC XBRL filing
- Revenue (annual): USD 570KSEC XBRL filing
- Operating cash flow (annual): USD -33.12MSEC XBRL filing
- Shares outstanding (annual): 33.32MSEC XBRL filing
- Current liabilities (annual): USD 2.4MSEC XBRL filing
- Long-term debt (annual): USD 0SEC XBRL filing
- Shareholders' equity (annual): USD 27.77MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-07-29 22:34 UTCEVENTHa Price Listing VYNE remains DEFICIENT (NASDAQ) — cure period. closed below $1.00 for 247 consecutive trading days (last close $0.939). cure deadline 2027-01-17 (172 days remaining).
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-05-29 00:00 UTCINSIDER1 insider transaction — 2026-05
2026-05-29INSIDERDomzalski David transacted 30.8k sh — Director, PRESIDENT AND CEO ~$10k
2026-03-31 00:00 UTCINSIDER4 insider transactions — 2026-03
2026-03-31INSIDERStuart Iain transacted 2.9k sh — CHIEF SCIENTIFIC OFFICER ~$2k
2026-03-31INSIDERDomzalski David transacted 14.2k sh — Director, PRESIDENT AND CEO ~$9k
2026-03-31INSIDERHarsch Mutya transacted 4.0k sh — CHIEF LEGAL OFFICER AND GC ~$2k
2026-03-31INSIDERZeronda Tyler transacted 4.0k sh — CHIEF FINANCIAL OFFICER ~$2k
2025-12-31 00:00 UTCINSIDER8 insider transactions — 2025-12 4 derivative
2025-12-31INSIDERHarsch Mutya transacted 3.6k sh — CHIEF LEGAL OFFICER AND GC ~$2k
2025-12-31INSIDERZeronda Tyler transacted 7.9k sh — CHIEF FINANCIAL OFFICER ~$5k
2025-12-31INSIDERDomzalski David transacted 12.7k sh — Director, PRESIDENT AND CEO ~$7k
2025-12-31INSIDERStuart Iain transacted 2.4k sh — CHIEF SCIENTIFIC OFFICER ~$1k
2025-12-12INSIDERBARBARI SHARON acquired 20.0k sh Stock Option (right to buy) — Director
2025-12-12INSIDERLEPORE PATRICK G acquired 20.0k sh Stock Option (right to buy) — Director
2025-12-12INSIDERLittle Elisabeth Sandoval acquired 20.0k sh Stock Option (right to buy) — Director
2025-12-12INSIDERBasta Steven L acquired 20.0k sh Stock Option (right to buy) — Director
2025-09-30 00:00 UTCINSIDER4 insider transactions — 2025-09
2025-09-30INSIDERDomzalski David transacted 12.7k sh — Director, PRESIDENT AND CEO ~$4k
2025-09-30INSIDERZeronda Tyler transacted 3.4k sh — CHIEF FINANCIAL OFFICER ~$1k
2025-09-30INSIDERStuart Iain transacted 2.5k sh — CHIEF SCIENTIFIC OFFICER ~$1k
2025-09-30INSIDERHarsch Mutya transacted 3.6k sh — CHIEF LEGAL OFFICER AND GC ~$1k
2025-06-30 00:00 UTCINSIDER6 insider transactions — 2025-06
2025-03-31 00:00 UTCINSIDER2 insider transactions — 2025-03
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage